Last reviewed · How we verify
NCT05827146
Study of Hepalatide in Chronic Hepatitis D(CHD) Patients
Phase 2 trial testing Hepalatide in Chronic Hepatitis D Infection in 23 participants. Completed in 1 February 2024.
30 January 2024
Quick facts
| Lead sponsor | Shanghai HEP Pharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 23 |
| Start date | 7 October 2023 |
| Primary completion | 30 January 2024 |
| Estimated completion | 1 February 2024 |
| Sites | 3 locations across China, Mongolia |
Drugs / interventions tested
- Hepalatide — full drug profile →
- Hepalatide Placebo — full drug profile →
Conditions studied
- Chronic Hepatitis D Infection — all drugs for Chronic Hepatitis D Infection →
Sponsor
Shanghai HEP Pharmaceutical Co., Ltd. — full company profile →
Who can join
Adults 18 to 65, any sex, with Chronic Hepatitis D Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A phase 2a clinical Study of Hepalatide for Injection in Subjects with Chronic Hepatitis D
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting NTCP for liver disease treatment: A promising strategy.
Tan X, Xiang Y, Shi J, Chen L, et al · · 2024 · cited 12× · PMID 39310850 · DOI 10.1016/j.jpha.2024.100979 -
[Current status of diagnosis and treatment and progress in drug research and development for hepatitis D].
Rao HY, Wei L. · · 2024 · PMID 39528333 · DOI 10.3760/cma.j.cn501113-20240612-00292
Verify or expand the search:
- PubMed search for NCT05827146
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Hepalatide
Trials testing the same drug.
- NCT05244057 — A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients · Phase 2 · completed
Other recruiting trials for Chronic Hepatitis D Infection
Currently open trials in the same condition.
- NCT07200908 — A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2) · Phase 3 · recruiting
- NCT06248580 — Find HDV and Determine Its Status in Turkey · recruiting
Other Shanghai HEP Pharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT05244057 — A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients · Phase 2 · completed
- NCT04426968 — A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis B · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05827146 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai HEP Pharmaceutical Co., Ltd.
- Last refreshed: 24 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05827146.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing